October 5-7 | Arizona Biltmore
Right. On Time. AGC Biologics is a leading global Contract Development and Manufacturing Organization (CDMO), providing world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), viral vectors and genetically engineered cells. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast track projects for orphan drugs and rare diseases. www.agcbio.com
Akron Bio enables the advancement of cell and gene therapies through its portfolio of cytokines and media supplements, as well as its comprehensive suite of manufacturing services, including the production of plasmid DNA, precision gene-editing tools, and specialized medias. Akron partners with advanced therapy developers, providing them with critical materials and services at the scale, level of compliance, and regulatory support necessary to drive novel treatments from discovery to commercialization, thereby addressing critical unmet needs in the patient community. www.akronbiotech.com
Founded in 1998, Aldevron is a global leader in enabling the development of next-generation genomic medicines. As part of Danaher Corporation, Aldevron empowers scientists and innovators worldwide to advance transformative therapies that are redefining the future of medicine. Aldevron’s expertise and integrated solutions have supported landmark achievements—including playing a key role in manufacturing the world’s first mRNA-based personalized CRISPR therapy. With facilities in Fargo, ND, Madison, WI and Waltham, MA, Aldevron is at the forefront of accelerating scientific discovery and expanding the possibilities of gene editing, gene therapy and other breakthrough modalities. By partnering with leading researchers and organizations, Aldevron is helping to turn the promise of genomic medicine into reality for patients around the globe.
The American Red Cross is a nationwide leader in providing allogeneic and autologous products and services for cell and gene therapy. Our services include CAR-T collection supporting all current FDA-approved T-cell therapies, processing, and storage within our five Manufacturing Science and Technology labs. We offer allogeneic starting materials, ranging from RUO to cGMP-compliant clinical grade that can be used to support your needs from bench research to late-stage development of life-saving therapies. With a national network of apheresis collection sites, we provide a large pool of recallable donors, allowing us to scale up to meet growing needs. Our Quality Management System provides one set of standards that limits variability, ensuring the consistency of your products. The American Red Cross Cell & Gene therapy team partners with clients throughout the entire process, from basic research and discovery to safety assessment and manufacturing of late-stage clinical trials. www.redcrossblood.org/cellulartherapy
Andelyn Biosciences is a full-service cell and gene therapy CDMO focused on the development, characterization and production of viral vectors for gene therapy. With more than 20 years of experience, Andelyn’s deep scientific expertise has resulted in the production of cGMP material for more than 450 clinical batches and 75 global clinical trials. Operating out of its development and manufacturing facilities in Columbus, Ohio, Andelyn supports its clients in developing cell and gene therapies from concept through plasmid engineering and manufacturing, process and analytical development, and cGMP clinical and commercial manufacturing. Andelyn can accelerate programs and deliver high quality products by developing and manufacturing processes on its configurable, data-driven AAV Curator Platform®, or tech transferring in an established client program. Capabilities include cGMP manufacturing for suspension processes up to a 2,000-liter and adherent processes. A rigorous quality system, regulatory support, and supply chain vertical integration further support clients in bringing their critical therapies to market.
Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Follow Arcellx on X (Twitter) at @arcellx and LinkedIn.
The Advanced Regenerative Manufacturing Institute (ARMI) is a member-based, nonprofit organization whose mission is to advance the bioeconomy of the United States. The institute’s work will positively impact not only manufacturing but also healthcare and education & workforce development for the nation.
BioFabUSA, a program of ARMI, is a public-private partnership with more than 200 members, including companies, academic institutions and not-for profit organizations. The mission of BioFabUSA is to bring together the fundamental tenets of good manufacturing processes and the science of regenerative medicine to create regenerative manufacturing and the trained and ready workforce necessary for that manufacturing.
Aseptic Technologies manufactures fill & finish equipment and devices for advanced pharmaceutical manufacturing. Our core expertise lays in the innovation of aseptic filling processes for biopharmaceutical products, including cell and gene therapy products. As a member of SKAN Group, we leverage technological excellence of SKAN in the isolator design, providing integrated solutions for fill & finish projects, globally. Furthermore, we share decades of expertise in injection molding and manufacturing in cleanroom, offering customized ready-to-use assemblies for pharmaceutical processes.
Asimov, the Boston-based synthetic biology company focused on mammalian cell engineering, recently launched our industry-leading cell lines for stable viral vector production. Originally developed at MIT, our platform radically advances the design and manufacture of gene therapies and biologics. By integrating state-of-the-art genetic engineering, computational biology, and automation, Asimov enables breakthrough solutions to long-standing challenges in industry. www.asimov.com
Beghou focuses on “Commercialization that Works” for the life sciences industry in areas such as rare diseases, oncology, neurology, and cell and gene therapies (CGT), helping specialty therapy companies navigate the complexities of commercialization as they transition from clinical to commercial stages. For over 30 years, Beghou has been a long-term consulting and technology partner to more than 200 life sciences clients. We connect the dots between strategy, data, technology, and teams – helping clients accelerate launches, deepen customer engagement, and advance patient access. Specifically for CGT, Beghou brings strategic and operational rigor to therapy launches, particularly those with high costs, limited patient populations, and unique engagement needs. Our tailored, therapy-specific approach ensures scalable infrastructure and measurable results across providers, payers, and patients. Beghou partners with clinical and commercialization leaders to move faster, plan smarter, and deliver precision-driven growth in complex therapeutic areas.
BlueRock Therapeutics is an engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. The company’s cell+gene platform enables the creation, manufacture, and delivery of authentic cell therapies with engineered functionality by simultaneously harnessing pluripotent cell biology and genome editing. This enables an approach where, in theory, any cell in the body can be manufactured and any gene in the genome can be engineered for therapeutic purposes. The platform is broadly applicable, but the company is focused today in neurology, cardiology, and immunology. In August 2019, the company was acquired by Bayer AG, for an enterprise value of $1B in upfront and milestone payments. For BlueRock this marks the next step in the journey to prove degenerative disease is reversible, and to bring our revolutionary new medicines to the patients who desperately need them.
Boston BioProducts was founded in 1995 by a group of research scientists from Harvard Medical School, with a strong passion for accelerating scientific discoveries. Since our founding, we’ve dedicated ourselves to providing high-quality reagent solutions for life science research in the biotech industry and academia. Boston BioProducts is a leading provider of biological buffers, media, and solutions for the life sciences. With nearly 30 years of experience in buffer and reagent manufacturing, our dedicated team of formulation scientists and in-house manufacturing capabilities support multiple applications including molecular biology, assay development, and bioprocessing.
Catalent Cell & Gene Therapy is an industry-leading technology, development, manufacturing, and analytical testing partner for advanced therapeutics. With deep expertise in viral vector development, scale-up and manufacturing for gene therapies and viral vaccines, Catalent is a full-service partner for Plasmid DNA, Adeno-associated Virus (AAV), Lentivirus and other viral vectors, and oncolytic viruses. Its comprehensive Cell Therapy portfolio includes a wide range of expertise across a variety of cell types including CAR-T, TCR, TILs, NKs, iPSCs, and MSCs. As an experienced and innovative partner, it has a global network of dedicated development, clinical and commercial manufacturing facilities, including an EMA- and FDA-licensed viral vector facility, fill/finish capabilities located in the U.S. and Europe and full service analytical testing. With integrated solutions for plasmid DNA, viral vectors and autologous and allogeneic cell therapies through clinical trial packaging and logistics, Catalent can provide full supply chain control as well as integrated or standalone analytical support to enable innovators to get their advanced therapies to patients faster.
Cellbox Solutions develops innovative logistics solutions for the global BioMed industry. Its flagship product, a portable incubator with active CO₂ and temperature control, ensures the safe transport of living cells and biological samples under optimal laboratory conditions. The concept originated at Fraunhofer EMB in Lübeck, where researchers needed a solution to transport fragile biological material and cells while maintaining constant conditions of 37°C and 5% CO₂. Within 18 months, a team of engineers and biologists developed fully functional and robust Cellbox™. Today, Cellbox Solutions collaborates closely with more than 150 customers to tackle diverse cell transport challenges and continuously improve its products. The development and assembly of Cellbox™ incubators were carried out in partnership with Fraunhofer EMB, and is now supported by an European EIC grant. Since this year, Cellbox™ has also established a collaboration with Biospherix, a US company specializing in closed-system cell culture technologies.
The complexities of cellular and gene therapy programs present scientific and technical challenges. They are highly customized and vary greatly based on product attributes. Now, because of tremendous promise to cure many types of diseases, there is a lot of pressure to move these programs through regulatory approval faster than ever. It is therefore crucial to find a single partner of choice who offers access to a deep scientific and regulatory network and integrates the various elements of your program to achieve your milestones and make it to market on time. With over 70 years of experience, Charles River has a unique and comprehensive portfolio to support the development and execution of cellular and gene therapy programs from animal model selection to discovery and safety evaluations through to clinical and CMC testing support. www.criver.com
Cryoport Systems is a comprehensive supply chain partner for the life sciences focused on the global cell and gene therapy market. We excel in the specialized management of the advanced therapy supply chain through our comprehensive offerings in shipping systems, logistics, BioServices and biostorage, cryopreservation services, and consulting. Our expansive offerings are fully integrated to create a comprehensive platform that helps deliver risk mitigation, transparency, and certainty throughout the supply chain. With our platform of scalable, risk-mitigation solutions, innovative technology, and dedicated team of people, Cryoport Systems is committed to going above and beyond to enable the outcomes for the advancing cell and gene therapy industry.
With a rich heritage dating back hundreds of years, Cytiva brings a wealth of technical expertise and talent, a broad and deep portfolio, and exceptional service help researchers and biopharma advance therapeutics at every stage from discovery to delivery. We supply the tools and support our customers need to work better, faster, and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, Sefia™, Whatman™, and Xcellerex™.
Dark Horse Consulting Group (DHCG) is a fully-integrated global consulting practice offering services across biopharma markets with a focus on CGT. Comprising two business units, Dark Horse Consulting (DHC) and BioTechLogic (BTL), we offer a broad scope of expertise, resources, and engagement types that uniquely positions us to serve a wide range of client types and address an extensive scope of challenges throughout full product and organizational lifecycle. Together, we apply best practices across industries to address the varied needs of our clients, who range from biopharma companies to tools/tech providers to VC/PE investors. DHC offers unmatched CGT expertise designed to close clients’ knowledge and expertise gaps, thus enabling them to accelerate their strategic objectives across CMC, regulatory, nonclinical, clinical, quality/compliance, and business analytics. BTL offers operational, execution-level experience and expertise to help clients bring products to market quickly and successfully with offerings in CMC, regulatory, and quality/compliance. Our joint cross-functional/cross-organizational teams are customized to meet the specific needs of our clients on a case-by-case basis.
www.darkhorseconsultinggroup.com | www.biotechlogic.com
Founded in 2015, Dot Compliance provides a ready-to-deploy, Salesforce-native eQMS with the industry’s first AI specifically built to deliver safe, reliable decision guidance for critical quality issues. This offers faster, more proactive quality and compliance through vertical AI that empowers data-driven decision making in life sciences quality and compliance. The company’s solutions are trusted by life sciences companies, both large and small, worldwide. Dot Compliance is certified with ISO/IEC 42001:2023, ISO 9001:2015, ISO 27001:2022 and ISO 27017:2015. All solutions are fully compliant with 21 CFR Part 11, 21 CFR Part 820, EU Annex 11 and support ISO 13485 and ISO 14971.
EBD Group’s overriding mission is to help collaborations get started across the life science value chain. Our range of partnering conferences has grown to become the largest and most productive conference platform in the industry. Each one of our seven landmark events held in key life science markets around the world is powered by our state-of-the-art partnering software, partneringONE, that enables delegates to efficiently identify and engage with new opportunities via one-to-one meetings. Today our events (BIO-Europe, BIO-Europe Spring, BioPharm America, Biotech Showcase, ChinaBio Partnering Forum, Cell & Gene Exchange, and BioEquity Europe) annually attract more than 12,000 senior life science executives who engage in over 43,000 one-to-one partnering meetings. These vital one-to-one engagements are the wellspring of deals that drive innovation in our industry. www.ebdgroup.com
ElevateBio is a technology-driven company built to power the development of transformative cell and gene therapies today and for many decades to come. The company has assembled industry-leading talent, built state-of-the-art facilities, and integrated diverse technology platforms, including gene editing, induced pluripotent stem cells (iPSCs), and protein, vector, and cellular engineering, necessary to drive innovation and commercialization of cellular and genetic medicines. In addition, BaseCamp is a purpose-built facility offering process innovation, process sciences, and current Good Manufacturing Practice (cGMP) manufacturing capabilities. Through BaseCamp and its enabling technologies, ElevateBio is focused on growing its collaborations with industry partners while also developing its own portfolio of cellular and genetic medicines. ElevateBio’s team of scientists, drug developers, and company builders are redefining what it means to be a technology company in the world of drug development, blurring the line between technology and healthcare. www.elevate.bio
Forge Biologics, a member of Ajinomoto Bio-Pharma Services, is a gene therapy contract development and manufacturing organization (CDMO) enabling access to life-changing gene therapies by bringing them from concept to reality. Forge’s 200,000 square foot facility, the Hearth, is headquartered in Columbus, Ohio, and houses 20 custom-designed cGMP suites with 20,000L of bioreactor capacity. Forge’s end-to-end, scalable plasmid and AAV manufacturing services include research-grade manufacturing, process and analytical development, cGMP manufacturing, fill and finish, and integrated regulatory support to help accelerate the timelines of transformative medicines for patients with genetic diseases.
Genezen is a best-in-class gene therapy CDMO with over a decade of experience supporting the cell and gene therapy manufacturing market worldwide. With capabilities across vector-modalities (AAV, lentiviral, retroviral, and others), Genezen partners with innovator organizations to deliver potentially life-saving gene and cell therapies – from concept to commercial. With flexible and customer-centric programs, Genezen tailors its partnership-model approach to all sizes and stages of organizations, to make viral vector production accessible to both early-stage, growth-oriented companies and established industry leaders. Genezen’s state-of-the art Lexington, MA site holds multiple global regulatory licenses, including with the FDA, EMA, Health Canada, and MFDS Korea, in support of the active manufacture of a commercial viral vector-based product. Our Indianapolis, IN site provides cGMP manufacturing for viral vectors and is currently supporting a program entering a pivotal clinical trial.
InspiroGene™ by McKesson specializes in advancing the commercialization of cell and gene therapies (CGT). InspiroGene is more than a partner—we’re an ally that collaborates with you to bridge the gap between innovation and reality. Our suite of integrated and scalable solutions is designed to meet both your current and future needs, unlocking the full potential of your CGT. With InspiroGene by your side, manufacturers and providers can be confident that patient access to CGT treatment is optimized and streamlined, with seamless integration from the warehouse to treatment center. Our distribution assets, cold chain storage and logistics solutions and innovative technology platforms empower stakeholders to manage, monitor, and deliver life-changing care faster and more efficiently. InspiroCare, our CGT-dedicated patient hub, is designed to provide personalized, compassionate support, ensuring that patients and their caregivers receive the guidance and resources they need. Our specialty pharmacy capability reduces product transit times and helps ensure timely and reliable delivery to treatment centers, all designed to help providers and patients access to life-changing therapies. InspiroGene is backed by over a decade of McKesson’s real-world CGT expertise and is committed to stakeholder collaborations that transform the care patients receive on their path to better health.
Because their lives are in our hands…
Depend on us to get it right.
The Japanese Society for Regenerative Medicine (JSRM) is the largest academic society in regenerative medicine globally, with over 6,000 members spanning diverse fields, including basic and clinical sciences, tissue engineering, bioethics, regulatory science, and health policy. JSRM serves as a multidisciplinary platform for researchers, clinicians, industry leaders, and policymakers to collaborate on regenerative medicine development and implementation. The society actively engages in policy advocacy, develops industry standards, and hosts international academic conferences to drive scientific and regulatory advancements in regenerative medicine.
Lonza is one of the world’s largest contract development and manufacturing organizations (CDMOs) dedicated to serving the healthcare industry. Working across five continents, our global team of around 18,500 colleagues works alongside pharma and biotech companies to turn their breakthrough innovations into viable therapies.
Machaon Diagnostics is a specialty laboratory helping clinical trials stay on track by providing fast testing. Our expertise in complement and immunology help you prepare for serious adverse events (SAEs) in your trials.
We support sponsors of cell and gene therapy trials by quickly testing for safety or biomarkers. Tests available with a turnaround time of <24 hours include:
Our speed sets us apart. We also offer sponsored testing and data sharing services. Machaon’s proprietary, real-time lab data identifies rare patients and samples within hematology, nephrology, and immunology indications. Samples come to us from all 50 US states and many countries worldwide.
For 22 years, Machaon has been a leader in serving medical centers, CROs, and biotech/pharmaceutical companies. Let us help you meet trial milestones while ensuring patient safety. Contact us to get input on your RFPs and study design.
MilliporeSigma is the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany. Our Millipore® CTDMO services provide a streamlined experience in a single partner to mitigate the burden of managing multiple vendors, supply chain needs, and complex priorities along the drug life cycle. Our integrated Millipore® CTDMO Services combines our expertise in development, manufacturing, contract testing and technologies from pre-clinical to commercial to accelerate your milestones and breakthroughs – with one experienced partner. www.SigmaAldrich.com/ViralVector
For 30 years, Miltenyi Biotec has been a leader in the design, development, manufacture, and integration of products that enable cell and gene therapy (CGT), leading to new treatment options for patients with unmet medical needs. With technologies ranging from clinical-grade cell separation platforms to tailored cell processing protocols for the fully automated and enclosed, GMP-compliant CliniMACS Prodigy®, we offer comprehensive CGT support, including contract development and manufacturing of CGT products and tailored GMP lentiviral vectors. Our products have been used in more than 50,000 cell therapy procedures. In addition, the automated CliniMACS® Cell Separation System, in combination with high-quality MACS GMP and CryoMACS® products, has been used for the consistent generation of cellular products that are used in a wide range of clinical applications. www.miltenyibiotec.com
Minaris Advanced Therapies is a global contract development and manufacturing organization (CDMO) and contract testing provider focused exclusively on cell and gene therapies. Minaris Advanced Therapies is headquartered in Philadelphia, Pennsylvania, and has more than 650,000 square feet of infrastructure across the United States, Europe, and Asia. We have manufactured and released over 7,500 GMP batches and our global network supports therapy developers through early-stage development, clinical trials, and commercial manufacturing. By combining scientific expertise with best-in-class manufacturing and testing services, we help bring safe, effective therapies to patients faster and more efficiently.
At Miromatrix, we are pioneering a novel technology with the goal of developing fully transplantable human organs. Using the science behind our patented technology, we are working to develop bioengineered human organs in hopes of providing new options for transplantation. We believe our approach may provide an efficient way to answer the unmet need of thousands of patients across the country who will otherwise go without the transplant they need to survive and thrive.
Moffitt Cancer Center is a renowned National Cancer Institute-designated Comprehensive Cancer Center based in Tampa, Florida. It is dedicated to the prevention and cure of cancer through research, education and patient care. Its unique ecosystem integrates preclinical development, translational research, and clinical care in collaboration with world-renowned scientific experts and leaders in the field of Cell and Gene Therapy. As part of this ecosystem, Moffitt’s onsite Cell Therapy and Gene Engineering facility provides GMP manufacturing of cell therapies and viral vectors for clinical trials, supporting both Moffitt faculty and industry partners. With over 15 years of expertise of translating cell therapy assets into the clinic, Moffitt has manufactured and supported over 50 INDs. Moffitt’s cell manufacturing expertise includes TILs, CAR-Ts (alpha beta & gamma delta), TCR-T, Tregs, and DC vaccines.
OXB, previously Oxford Biomedica, is a global quality and innovation-led CDMO in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. To discuss your viral vector needs email partnering@oxb.com.
Parexel is a global clinical research organization (CRO) with a focus on community, providing the full range of Phase I to IV clinical development services to help life-saving treatments reach patients faster. We advance cell and gene therapy trials by focusing on empirical data, lived experience, and pragmatic innovation to accelerate clinical development. With comprehensive insights from former regulators and experienced operational delivery units from around the world, we help sponsors navigate new and evolving regulatory and manufacturing challenges, operational complexities, and obstacles to market and patient access. Leveraging the breadth of our clinical, regulatory and therapeutic expertise, our team of more than 21,000 clinical research professionals works in partnership with biopharmaceutical leaders, emerging innovators and study sites to design and deliver cutting edge clinical trials that differentiate in time and space. We believe that increasing access and participation to advanced therapy clinical studies should be a care option for anyone, anywhere. Our industry knowledge and record of 40 years of developing novel therapies gives us the opportunity to proactively address healthcare’s most complex diseases, while our innovation efforts offer data-driven solutions to make each phase of the clinical trial process more efficient while decreasing sponsor spend. Parexel works With HeartTM so that every trial can make a difference. This approach continues to work for us, with Parexel being the recipient of the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award for advancing the clinical research profession through strong site partnerships and named “Top CRO to Work With” by investigative sites worldwide in the 2023 WCG CenterWatch Global Site Relationship Benchmark Survey.
RoslinCT is a leading global contract development and manufacturing services organization (CDMO) focused on Advanced Cell and Gene Therapies. Established in 2006 and built upon the groundbreaking technology cloning of Dolly the Sheep at the Roslin Institute in 1997, RoslinCT has harnessed cutting-edge science to advance the development of human medicines. With a remarkable heritage in the field, the company has achieved significant milestones, including being among the first in the world to produce clinical-grade human pluripotent stem cells and advancing the first CRISPR edited stem cell-based therapy for a major disease to marketing authorization. Equipped with 22 purpose-built cGMP cell therapy processing suites in Edinburgh, Scotland, and Hopkinton, Massachusetts, RoslinCT provides innovative process and analytical development, cGMP clinical and commercial manufacturing for a range of cell types for both autologous and allogeneic processes, and cGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, RoslinCT enables partners to efficiently progress from development to commercialization and deliver life-saving Cell and Gene Therapies worldwide.
ScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world’s most practical, flexible, scalable, and affordable CGT drug product development and manufacturing. The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 5 commercially approved CGT drugs. CGT entities relying on the breadth and scope of ScaleReady’s expertise can expect to save years of time and millions of dollars on the path to CGT commercialization. For more information about the ScaleReady G-Rex® Grant Program, please contact info@scaleready.com.
SK pharmteco is a global contract development and manufacturing organization (CDMO) with 13 offices and manufacturing facilities across the U.S., Europe, and Korea. The company partners with biopharmaceutical companies of all sizes to manufacture Active Pharmaceutical Ingredients (API) and intermediates, cell and gene therapy technologies, registered starting materials, and analytical services for the biopharmaceutical industry worldwide. SK pharmteco is a subsidiary of SK Inc. (KRX: 034730) (SK), the strategic investment company for SK Group, South Korea’s second-largest conglomerate.
More than 50 years of experience have made Technoflex, Worldwide leader in design and manufacture of flexible bags with associated connectors for the pharmaceutical industry. Our cutting-edge technology and internal R&D resources enable us to provide all-inclusive innovative solutions, reliable and easy-to-use. By working well upstream of its customers’ requirements and by anticipating the technical, environmental and regulatory changes, Technoflex optimize the design of the future generations of flexible bags and associated connectors. Our proficiency of the manufacturing process in clean room ISO 7 (Class 10000) allows us to provide innovative containers with a low AQL (no leaks, no particles). The different ranges of bags, Inerta®, Dual-Mix®, ReadyMix®, Clarima®, Biocell®, Cryocell®, SafeCell®, Cellflex®, developed by Technoflex are designed for various application such as: IV therapies, Compounding, Nutrition, Cell therapies, Biotherapies, Bioprocessing. All our bags are compliant with the European and American pharmacopoeias (FDA: DMF #19057) and provide customizable options on demand.
Teknova expedites breakthroughs in modern medicine by providing critical reagents for the production of molecular diagnostics, novel vaccines, and next-generation therapies. With a focus on quality, speed, and service, we manufacture custom solutions that are used at every stage of the product development workflow, from early-stage research through process development and clinical manufacturing. To meet the special demands of emerging therapies, our ISO 13485 certified production facilities were built with flexibility in mind, allowing us to quickly adapt our manufacturing setup to satisfy unique requests. With almost 30 years of formulation, dispense, and QC expertise, we are able to deliver custom research and GMP products with exceptionally fast turnaround times, in formats that allow seamless integration into customer-specific workflows.
Tenaya Therapeutics is a biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Tenaya is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. Founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is backed by an established syndicate of investors. www.tenayatherapeutics.com
Touchlight is an innovation-driven leading CDMO pioneering enzymatic GMP DNA production to enable the genetic medicine revolution. As pioneers with an FDA Drug Master Filing accepted in 2022 followed in 2025 with the world’s first GMP license, Touchlight’s enzymatic DNA technology is on the cutting edge of AAV, mRNA, DNA vaccine, and gene editing innovation. With multiple client products already in the clinic, Touchlight’s evidence-based, synthetic DNA manufacturing solutions offer a scalable, sustainable alternative to plasmid DNA (pDNA) for all stages of pre-clinical, clinical and commercial development. The company and technology are built on the conviction that DNA is fundamental to the future of medicine. Traditional methods, based on bacterial fermentation, are slow, costly, and unable to meet the growing demands of genetic medicine due to limited scalability and speed. Founded in 2007, Touchlight’s team is inspired by breakthroughs in genetic medicine, recognizing the urgent need for innovative DNA production techniques to support the future of genetic therapies.
Viralgen is a CDMO specializing in the production of recombinant Adeno-Associated Viral vectors. Viraglen was created in 2017 to respond to the unmet need for manufacturing of gene therapies, with the goal to help broaden access to these life-saving therapeutics and to contribute to the advancement of health and human welfare around the world. We have built an optimized facility in San Sebastian, Spain that maximizes throughput and efficiency of our proprietary Pro10™ suspension manufacturing platform, enabling industry-leading scalability, reproducibility, and speed to market. Through our superior technology platform, we deliver industry-leading titers and cGMP-certified quality for all AAV serotypes to our client partners, optimizing the cost-of-goods and accelerating clinical development and commercialization of life-changing genetic medicines.
Virica develops viral enhancers which optimize the manufacturing of viral medicines, allowing developers to economically deploy their products at scale. Virica’s Viral Sensitizer (VSE™) platform reduces production inefficiencies caused by innate antiviral defenses in manufacturing cells. Our purpose developed VSE formulations substantially increase manufacturing yields and reduce the cost of goods for a range of products, including vaccines, gene therapies, and cell therapies. www.viricabiotech.com